Your browser doesn't support javascript.
loading
The case for an HIV cure and how to get there.
Dybul, Mark; Attoye, Timothy; Baptiste, Solange; Cherutich, Peter; Dabis, François; Deeks, Steven G; Dieffenbach, Carl; Doehle, Brian; Goodenow, Maureen M; Jiang, Adam; Kemps, Dominic; Lewin, Sharon R; Lumpkin, Murray M; Mathae, Lauren; McCune, Joseph M; Ndung'u, Thumbi; Nsubuga, Moses; Peay, Holly L; Pottage, John; Warren, Mitchell; Sikazwe, Izukanji.
Afiliación
  • Dybul M; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA. Electronic address: mrd54@georgetown.edu.
  • Attoye T; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Baptiste S; International Treatment Preparedness Coalition, Johannesburg, South Africa.
  • Cherutich P; Kenya Ministry of Health, Nairobi, Kenya.
  • Dabis F; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales, Paris, France.
  • Deeks SG; University of California, San Francisco, California, USA.
  • Dieffenbach C; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.
  • Doehle B; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Goodenow MM; Office of AIDS Research, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.
  • Jiang A; McKinsey & Company Secondee at The Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Kemps D; Sommartel, London, UK.
  • Lewin SR; Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
  • Lumpkin MM; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Mathae L; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA.
  • McCune JM; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Ndung'u T; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban South Africa; Max Planck Institute for Infection Biology, Berlin, Germany; University College London, London, UK.
  • Nsubuga M; Joint Adherent Brothers & Sisters Against AIDS, Kampala, Uganda.
  • Peay HL; RTI International, Research Triangle Park, NC, USA.
  • Pottage J; Viiv Healthcare, Brentford, UK.
  • Warren M; AIDS Vaccine Advocacy Coalition, New York, NY, USA.
  • Sikazwe I; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Lancet HIV ; 8(1): e51-e58, 2021 01.
Article en En | MEDLINE | ID: mdl-33271124
In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 Problema de salud: 11_delivery_arrangements / 11_multisectoral_coordination / 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_enfermedades_transmissibles Asunto principal: Infecciones por VIH / VIH Tipo de estudio: Prognostic_studies Aspecto: Equity_inequality / Patient_preference Límite: Humans Idioma: En Revista: Lancet HIV Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 11_ODS3_cobertura_universal / 1_ASSA2030 / 2_ODS3 Problema de salud: 11_delivery_arrangements / 11_multisectoral_coordination / 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_enfermedades_transmissibles Asunto principal: Infecciones por VIH / VIH Tipo de estudio: Prognostic_studies Aspecto: Equity_inequality / Patient_preference Límite: Humans Idioma: En Revista: Lancet HIV Año: 2021 Tipo del documento: Article
...